Health and Fitness Health and Fitness
Tue, June 16, 2009
Mon, June 15, 2009
Fri, June 12, 2009
Thu, June 11, 2009
Wed, June 10, 2009
Tue, June 9, 2009
Mon, June 8, 2009
Sun, June 7, 2009
Fri, June 5, 2009
Thu, June 4, 2009
Wed, June 3, 2009
Tue, June 2, 2009
Mon, June 1, 2009
Sat, May 30, 2009
Fri, May 29, 2009
Thu, May 28, 2009
Wed, May 27, 2009
Tue, May 26, 2009
Mon, May 25, 2009
Fri, May 22, 2009
Thu, May 21, 2009
Wed, May 20, 2009
Tue, May 19, 2009
Mon, May 18, 2009
Fri, May 15, 2009
Thu, May 14, 2009
Wed, May 13, 2009
Tue, May 12, 2009
Mon, May 11, 2009
Fri, May 8, 2009
Thu, May 7, 2009
Thu, April 16, 2009
Wed, April 15, 2009
Tue, April 14, 2009
Mon, April 13, 2009
Fri, April 10, 2009
Thu, April 9, 2009
Wed, April 8, 2009
Tue, April 7, 2009
Mon, April 6, 2009
Fri, April 3, 2009
Thu, April 2, 2009
Wed, April 1, 2009
Tue, March 31, 2009
Mon, March 30, 2009
Fri, March 27, 2009
Thu, March 26, 2009
Wed, March 25, 2009
Tue, March 24, 2009
Mon, March 23, 2009
Fri, March 20, 2009
Thu, March 19, 2009
Wed, March 18, 2009
Tue, March 17, 2009
Mon, March 16, 2009
Sun, March 15, 2009
Fri, March 13, 2009
Thu, March 12, 2009

Molecular Insight Pharmaceuticals, Inc. : Molecular Insight Pharmaceuticals Expands Management Team by Appointing Daniel L. Pet


//health-fitness.news-articles.net/content/2009/ .. -management-team-by-appointing-daniel-l-pet.html
Published in Health and Fitness on Wednesday, May 13th 2009 at 3:26 GMT, Last Modified on 2009-05-13 03:28:41 by Market Wire   Print publication without navigation


CAMBRIDGE, MA--(Marketwire - May 13, 2009) - The Board of Directors of Molecular Insight Pharmaceuticals, Inc. (NASDAQ: [ MIPI ]) announced today that Daniel L. Peters has been appointed President and Chief Executive Officer. Mr. Peters was also elected to Molecular Insight's Board of Directors. Mr. Peters assumes the positions that had been held by John W. Babich, Ph.D., a Company founder, who will now serve as Executive Vice President, Chief Scientific Officer and President of Research and Development and continue as a member of the Board of Directors.

In announcing the appointment, Molecular Insight Board Chairman Anthony F. Martin, Ph.D., said, "Dan Peters is an excellent addition to our management team at this stage of the Company's development. He has overseen global operations and executed growth strategies for GE Healthcare's $2B Medical Diagnostics Division, so he is intimately familiar with our markets. In addition, Dan offers an impressive breadth of management expertise and commercial acumen. As partnership opportunities emerge to support our commercialization efforts, Dan's business experience will be important in driving our growth strategy and in continuing to enhance stockholder value."

Mr. Peters commented, "Molecular Insight's growth potential is what attracted me to the Company. Molecular Insight has carved out an impressive niche in the emerging field of molecular medicine. The Company has built a diverse pipeline of exciting product candidates that address unmet medical needs and cost-containment issues that capture daily headlines. It also appears to have in place strong clinical, regulatory and research groups. I am excited to be joining a team that already has created significant value."

The Board also announced that Dr. Babich, the Company's Chief Scientific Officer, will assume the additional key roles of Executive Vice President and President of Research and Development. Dr. Babich will continue his leadership responsibilities for driving the Company's scientific strategy, as well as continue the expansion and clinical development of the Company's robust pipeline of radiopharmaceutical compounds. This new role recognizes and builds upon Dr. Babich's unique value not just to Molecular Insight but also to the scientific community overall.

Dr. Babich commented, "I am looking forward to working closely with Mr. Peters in developing long-term strategies for growth and value creation. His strong commercial background within the industry is a great match for the innovative science that we have developed and are on the verge of bringing to market."

About Mr. Peters

Mr. Peters most recently served as President and Chief Executive Officer of the Medical Diagnostics business of GE Healthcare. GE Medical Diagnostics develops, manufactures and markets a broad portfolio of diagnostic pharmaceuticals, including radiopharmaceuticals that are used to provide early health information in cardiology, oncology, neurology and urology. Mr. Peters had responsibility for all aspects of the business including, but not limited to, the global P&L, long-term growth strategies, marketing, sales, business development, R&D and manufacturing. During his tenure with the unit, annual revenues grew, on average, at 10 percent. As CEO, Mr. Peters was actively involved in the development of the growth strategies for expansion of the business beyond its then-current portfolio. Under his leadership, the radiopharmaceutical business of Amersham Health was also successfully integrated into GE Healthcare, taking the more descriptive name of Medical Diagnostics.

Prior to joining GE Healthcare, Mr. Peters had been Chief Operating Officer of Amersham Health where he had worldwide operational responsibilities for all aspects of the business. While at Amersham and in addition to his regular operational duties, Mr. Peters played a key role in recruiting new talent to strengthen the R&D organization and in reorganizing the business structure to place more focus on emerging markets.

Earlier in his career, Mr. Peters was President of Nycomed Amersham, Inc., a $500 million North and South America diagnostic and therapeutic pharmaceutical subsidiary of Amersham Plc. of the U.K.

Mr. Peters also served as President of Nycomed, Inc. and held executive positions of increasing responsibility including the role of President of the U.S. pharmaceuticals business for Sanofi Winthrop Pharmaceuticals.

In each of Mr. Peters' roles, he has successfully built teams that effectively work across all segments of the business, forging strong working units focused on operational success, delivering results and value creation.

Mr. Peters' experience in developing business strategies, assessing market opportunities, launching new products and structuring companies for growth will serve Molecular Insight well as the Company moves into its next stage of product development, strategic partnering and product launch.

Mr. Peters, who holds a bachelor's degree from Western Illinois University, is currently Chairman of the Board of Phadia AB, and also serves on the boards of MDRNA, Inc. He also has been a member of the boards of the Healthcare Institute of New Jersey and the Pharmaceutical Researchers and Manufacturers of America.

About Molecular Insight Pharmaceuticals, Inc.

Molecular Insight Pharmaceuticals (NASDAQ: [ MIPI ]) is a Cambridge, Massachusetts-based biopharmaceutical company focused on the discovery and development of innovative radiopharmaceuticals in the emerging field of molecular medicine. These novel radiopharmaceuticals will provide important improvements in disease detection and enable the delivery of radiation therapy to widespread metastatic cancers. We have focused the initial applications of our proprietary technologies in the areas of cardiology and oncology. Molecular Insight's lead molecular imaging radiopharmaceutical product candidate, Zemiva™, is being developed for the diagnosis of cardiac ischemia, or insufficient blood flow to the heart. The Company's imaging candidate, Trofex™, is in development for the detection of metastatic prostate cancer. Molecular Insight's lead molecular radiotherapeutic product candidates, Azedra™, Onalta™, and Solazed™, are being developed for detection and treatment of cancer. In addition, the Company's discovery efforts continue to identify early-stage candidates -- a product of our in-house scientific expertise and the application of our proprietary platform technologies. For more information, visit [ http://www.molecularinsight.com ].

Forward-Looking Statements

Statements in this release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, statements about the development of Zemiva™, Trofex™, Azedra™, Onalta™, Solazed™, and our other product candidates. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause the actual results of Molecular Insight to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These factors include, but are not limited to, risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for product candidates; competition from other pharmaceutical or biotechnology companies; and the additional risks discussed in filings with the Securities and Exchange Commission (SEC). The Company's SEC filings are available through the SEC's Electronic Data Gathering Analysis and Retrieval system (EDGAR) at [ http://www.sec.gov ]. Press releases for Molecular Insight Pharmaceuticals, Inc. are available on our website: [ http://www.molecularinsight.com ]. If you would like to receive press releases via e-mail, please contact: [ investor@molecularinsight.com ]. All forward-looking statements are qualified in their entirety by this cautionary statement, and Molecular Insight undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.


Publication Contributing Sources

Similar Health and Fitness Publications